Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Daniel Everitt"'
Autor:
Francesca Conradie, Anna Vassall, Norbert Ndjeka, Gabriela Beatriz Gomez, Mariana Siapka, Anna Marie Celina Garfin, Nino Lomtadze, Zaza Avaliani, Nana Kiria, Shelly Malhotra, Sarah Cook-Scalise, Sandeep Juneja, Daniel Everitt, Melvin Spigelman
Publikováno v:
BMJ Open, Vol 11, Iss 12 (2021)
Externí odkaz:
https://doaj.org/article/34e7c4ff8d494dee9d5db81d5f531aa8
Autor:
Francesca, Conradie, Tatevik R, Bagdasaryan, Sergey, Borisov, Pauline, Howell, Lali, Mikiashvili, Nosipho, Ngubane, Anastasia, Samoilova, Sergey, Skornykova, Elena, Tudor, Ebrahim, Variava, Petr, Yablonskiy, Daniel, Everitt, Genevieve H, Wills, Eugene, Sun, Morounfolu, Olugbosi, Erica, Egizi, Mengchun, Li, Alda, Holsta, Juliano, Timm, Anna, Bateson, Angela M, Crook, Stella M, Fabiane, Robert, Hunt, Timothy D, McHugh, Conor D, Tweed, Salah, Foraida, Carl M, Mendel, Melvin, Spigelman, Adam A, Witney
Background\ud The bedaquiline–pretomanid–linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. The appropriate dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e75b3743b92e3e20f2adaedefafd0c1
https://openaccess.sgul.ac.uk/id/eprint/114768/1/NEJMoa2119430.pdf
https://openaccess.sgul.ac.uk/id/eprint/114768/1/NEJMoa2119430.pdf
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
Autor:
Francesca Conradie, G Wills, M. Olugbosi, A Calatroni, Mendel Carl M, Pauline Howell, Daniel Everitt, E Sun, N Ngubane, Aliasgar Esmail, A. del Parigi, Angela M. Crook, Melvin Spigelman, Andreas H. Diacon, Olatunde Olayanju, Keertan Dheda, Suzette Oelofse
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 25:453-460
BACKGROUND: There are no data comparing the 6–9 month oral three-drug Nix regimen (bedaquiline, pretomanid and linezolid [BPaL]) to conventional regimens containing bedaquiline (B, BDQ) and linezolid (L, LZD).METHODS: Six-month post end-of-treatmen
Autor:
Mamodikoe Makhene, Blaire Osborn, Wael El-Amin, George A Saviolakis, Tian J. Yang, Mengchun Li, Jerry R Nedelman, Daniel Everitt
Publikováno v:
Clinical Pharmacology in Drug Development
Tuberculosis (TB) continues to be a serious threat to public health throughout the world. Newer treatments are needed that could offer simplified regimens with activity against both drug‐sensitive and drug‐resistant bacilli, while optimizing safe
Autor:
Francesca, Conradie, Andreas H, Diacon, Nosipho, Ngubane, Pauline, Howell, Daniel, Everitt, Angela M, Crook, Carl M, Mendel, Erica, Egizi, Joanna, Moreira, Juliano, Timm, Timothy D, McHugh, Genevieve H, Wills, Anna, Bateson, Robert, Hunt, Christo, Van Niekerk, Mengchun, Li, Morounfolu, Olugbosi, Melvin, Spigelman, Priya, Solanki
Publikováno v:
The New England Journal of Medicine
Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatmen
Autor:
Daniel Everitt, Sandeep Juneja, Anna Marie Celina Garfin, Nino Lomtadze, Norbert Ndjeka, Shelly Malhotra, Sarah Cook-Scalise, Anna Vassall, Gabriela B. Gomez, Zaza Avaliani, Francesca Conradie, Nana Kiria, Melvin Spigelman, Mariana Siapka
Publikováno v:
BMJ Open, Vol 11, Iss 12 (2021)
BMJ Open
BMJ Open
ObjectivesPatients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introduci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4400a7e90ee145154e658f491b57d743
Autor:
G Wills, Andrew J. Nunn, J. Caoili, Mookho Malahleha, Francis Apolinary Mhimbira, Issa Sabi, Muge Cevik, Cheryl Louw, Anna Bateson, Ahmad Izuanuddin Ismail, M. C. Betteridge, Mendel Carl M, Ebrahim Variava, Daniel Everitt, Vincent Balanag, Suzanne Staples, Ronelle Moodliar, Umesh G. Lalloo, L. Lombard, Stephen H. Gillespie, Richard E. Chaisson, Robert D Hunt, Angela M. Crook, Videlis Nduba, Modulakgotla Sebe, Conor D. Tweed, Susan Swindells, Melvin Spigelman, A. Y.L. Ban, Evans Amukoye, C. H. van Niekerk, Andreas H. Diacon, Stella M. Fabiane, A. del Parigi, Rodney Dawson, R. A. P. Selepe, Francesca Conradie, Timothy D. McHugh, William Brumskine
Publikováno v:
The International Journal of Tuberculosis and Lung Disease
STAND was sponsored by TB Alliance with support from the UK Department for International Development, UK Department of Health (London, UK), Bill and Melinda Gates Foundation (Seattle, WA, USA), US Agency for International Development (Washington DC,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23754b0fb1db6916b0fbc5f98df336b9
https://hdl.handle.net/10023/21773
https://hdl.handle.net/10023/21773
Autor:
Mahmoud Tareq Abdelwahab, Gary Maartens, Daniel Everitt, Paolo Denti, Richard Court, Rodney Dawson, Andreas H. Diacon, Elin M. Svensson
Publikováno v:
Antimicrobial Agents and Chemotherapy, 65, 7
Antimicrobial Agents and Chemotherapy, 65
Antimicrob Agents Chemother
Antimicrobial Agents and Chemotherapy, 65
Antimicrob Agents Chemother
Contains fulltext : 235750.pdf (Publisher’s version ) (Closed access) Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis. QT prolongation, which is associated with fatal cardiac arrhythmias, is caus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47072d81e97f4d7f9e09b44a8f7d265f
https://repository.ubn.ru.nl/handle/2066/235750
https://repository.ubn.ru.nl/handle/2066/235750
Autor:
Vishak Subramoney, Jerry R Nedelman, David H Salinger, Mengchun Li, Mel Spigelman, Rob Woolson, Daniel Everitt, Mendel Carl M, Karen Wade
Publikováno v:
Antimicrobial Agents and Chemotherapy
Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intoleran
Autor:
Jerry R Nedelman, Naadira Vanker, Divan Aristo Burger, Andreas H. Diacon, Rodney Dawson, Daniel Everitt, Kim Narunsky, Veronique R. de Jager, Frances Pappas, Mendel Carl M
Publikováno v:
Antimicrobial Agents and Chemotherapy. 64